Answers are grounded in this paper and cite their sources.
Model demonstrates dynamic CAP binding landscapes in cell types, suggesting new regulatory genomics insights.
Chromatin-associated proteins (CAPs), including over 1,600 transcription factors, bind directly or indirectly to the genomic DNA to regulate gene expression and determine a myriad of cell types. Mapping their genome-wide binding and co-binding landscape is essential towards a mechanistic understanding of their functions in gene regulation and resulting cellular phenotypes. However, due to the lack of techniques that effectively scale across proteins and biological samples, their genome-wide binding profiles remain challenging to obtain, particularly in primary cells. Here we present Chromnitron, a multimodal foundation model that accurately predicts CAP binding landscapes across hundreds of proteins in unseen cell types. Via in silico perturbation experiments, we show that the model learned principles of CAP binding from multimodal features including DNA sequence motifs, chromatin accessibility levels, and protein functional domains. Applying Chromnitron to study cell fate transitions, we discovered novel CAPs regulating the T cell exhaustion process. Furthermore, Chromnitron can predict the dynamic CAP binding landscapes during development, revealing the global orchestration of protein and regulatory element activities in neurogenesis. We expect Chromnitron to accelerate discovery and engineering in regulatory genomics, particularly in human primary cells, and empower future therapeutic opportunities.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: